Last reviewed · How we verify
NCT04926688
High-risk Breast Lesions: A Multicenter Retrospective Study
trial in Premalignant Lesion in 1,345 participants. Completed in 10 June 2021.
20 January 2021
Quick facts
| Lead sponsor | Ege University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,345 |
| Start date | 10 June 2020 |
| Primary completion | 20 January 2021 |
| Estimated completion | 10 June 2021 |
| Sites | 1 location across Turkey (Türkiye) |
Conditions studied
- Premalignant Lesion — all drugs for Premalignant Lesion →
Sponsor
Ege University
Who can join
Eligibility, female only, with Premalignant Lesion. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In this multicenter study, the goal was to document the excisional biopsy or follow-up results of high risk lesions diagnosed on image guided CNB/VAB, and evaluate the clinical, imaging and histologic features for associated malignancy risk. The possibility of upgrade related to histologic subtype, tissue sampling and other variables was also evaluated.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04926688
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Premalignant Lesion
Currently open trials in the same condition.
- NCT07056374 — Adaptive Anastomosis for Anterior Resection in Sigmoid and Proximal Rectal Cancer or Premalignant Lesions · recruiting
- NCT06561087 — Phase II Randomized, Placebo- Controlled Study of Intralesional Nivolumab for High-risk Oral Premalignant Lesions · Phase 2 · recruiting
- NCT05762991 — Application of Artificial Intelligence on the Diagnosis of Helicobacter Pylori Infection and Premalignant Gastric Lesion · recruiting
- NCT06728631 — Candonilimab and ATRA Acid for Prevention of Oral Cancer Recurrence in Patients With OPL · Phase 2 · active not recruiting
- NCT03546972 — Diabetes Prevention Program With or Without Hunger Training in Helping to Lower Breast Cancer Risk in Obese Participants · NA · active not recruiting
Other Ege University trials
Trials by the same sponsor.
- NCT07468227 — Effect of Helfer Skin Tap and Vibration on Pain and Fear in Children During Intramuscular Injection · NA · not yet recruiting
- NCT07473050 — Virtual Reality-Based 'Health at My Feet' Program for Individuals With Type 2 Diabetes · NA · not yet recruiting
- NCT06955338 — Music and VR Effects on Pain, Anxiety, and Fear During Oral Mucositis Care in Leukaemic Children · NA · not yet recruiting
- NCT07344532 — Effect of Preoperative Abdominal Effleurage on Postoperative Constipation · NA · not yet recruiting
- NCT07417748 — Kinesthetic Exercises on Adults · NA · active not recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04926688 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ege University
- Last refreshed: 2 May 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04926688.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing